ArticleFrontiers in oncology2024
Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Fluid Suppression Techniques Combined With Amide Proton Transfer-Weighted Imaging for the Evaluation of Adult-Type Diffuse Gliomas.Korean journal of radiology · 2026Article
- Field strength-dependent sensitivity of chemical exchange saturation transfer: a methodological comparison of 3 Tesla and 7 Tesla in a clinical cohort.Brain communications · 2026Article
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- MixBranchNet: a task-adaptive network for glioma segmentation and genotype prediction by exploiting spatial-spectral correlations in CEST MRI.Frontiers in oncology · 2026Article
- Diagnostic performance of amide proton transfer-weighted imaging and four advanced diffusion-weighted MRI models for meningioma grading and subtyping.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To comprehensively and noninvasively predict glioma grade, IDH mutation status, 1p/19q codeletion status, and MGMT promoter methylation status using chemical exchange saturation transfer (CEST)-based tumor pH assessment and metabolic profiling. Methods: We analyzed 128 patients with pathologically confirmed adult diffuse glioma. CEST-derived metrics based on tumor regions were obtained using five-pool Lorentzian analysis and pH_weighted analysis. Histogram features of these metrics were computed to characterize tumor heterogeneity. These features were subsequently employed for glioma grading and molecular genotyping of IDH, 1p/19q and MGMT. Logistic regression analysis was used to predict the grade and IDH genotypes. The diagnostic performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis. Results: The DS, MT and pH_weighted differed significantly between grade II and III, as well as grade III and IV. The amide, NOE, pH_weighted and MTR Conclusion: CEST-based tumor pH assessment and metabolic profiling demonstrated promising potential for predicting glioma grade, IDH mutation status, 1p/19q codeletion, and MGMT genotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.